Drug
Tavapadon clinical trials
Also written PF-06649751 and CVL-751.
- studies test it
- 19
- open now
- 0
- in phase 3
- 4
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 2
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 0
Often tested with
Tested in the same studies.
Carbamazepine (1) · Itraconazole (1) · Trimethobenzamide (1)
Studies
Open first, then newest update. How each study uses tavapadon is read from its arms, and is right about nine times in ten.
Testing it · 19
- Open-label Trial in Parkinson's Disease (PD)CompletedPhase 3AbbVieNCT04760769Written as Tavapadon
- Flexible-Dose Trial in Early Parkinson's Disease (PD)CompletedPhase 3AbbVieNCT04223193Written as Tavapadon
- Fixed-Dose Trial in Early Parkinson's Disease (PD)CompletedPhase 3AbbVieNCT04201093Written as Tavapadon
- A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult ParticipantsCompletedPhase 1AbbVieNCT06895356Written as Tavapadon
- Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)CompletedPhase 3AbbVieNCT04542499Written as Tavapadon
- To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal FunctionCompletedPhase 1Cerevel Therapeutics, LLCNCT05404542Written as Tavapadon
- Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's DiseaseCompletedPhase 1Cerevel Therapeutics, LLCNCT05610189Written as Tavapadon
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's DiseaseCompletedPhase 1PfizerNCT02373072Written as PF-06649751
- To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCompletedPhase 1Cerevel Therapeutics, LLCNCT05404529Written as Tavapadon
- Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult ParticipantsCompletedPhase 1Cerevel Therapeutics, LLCNCT05581823Written as Tavapadon
- A 2-Part Trial of CVL-751 in Subjects With Parkinson's DiseaseCompletedPhase 1Cerevel Therapeutics, LLCNCT04295642Written as CVL-751
- Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the DiseaseTerminatedPhase 2PfizerNCT02847650Written as PF-06649751
- Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsTerminatedPhase 2PfizerNCT02687542Written as PF-06649751 low dose (1 mg QD)
- An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy SubjectsCompletedPhase 1Cerevel Therapeutics, LLCNCT04241393Written as Tavapadon tablet
- A Study To Estimate The Effects Of Itraconazole On Pharmacokinetics Of Pf-06649751 In Healthy Adult SubjectsCompletedPhase 1PfizerNCT03121664Written as PF06649751, Itraconazole
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's DiseaseCompletedPhase 1PfizerNCT02224664Written as PF-06649751
- A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese VolunteersCompletedPhase 1PfizerNCT02066909Written as 0.15 mg PF-06649751
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy SubjectsCompletedPhase 1PfizerNCT02262767Written as PF-06649751
- A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751CompletedPhase 1PfizerNCT01981694Written as PF-06649751
Codes
What other systems call tavapadon · ClinicalTrials.gg INT017611
- UNII (FDA) PT4P8MJP8LTAVAPADONConfirmed FDA, Wikidata
- Wikidata Q108670876tavapadonConfirmed FDA, Wikidata
- NCI Thesaurus C174853TavapadonOne source FDA
- DrugBank DB14899One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PT4P8MJP8L | TAVAPADON | Confirmed FDA, Wikidata |
| Wikidata | Q108670876 | tavapadon | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174853 | Tavapadon | One source FDA |
| DrugBank | DB14899 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.